The company’s founder and president Dr S.K. Dash said the formulas were targeted at different conditions and were backed by many studies both published and unpublished.
The four blends are:
- L. acidophilus DDS-1, Bifidobacterium longum plus FOS (5 billion CFU/gram)
- L. acidophilus DDS-1, B. lactis plus FOS (5 billion CFU/gram)
- L. acidophilus DDS-1, B. longum, B. lactis, B. bifidum plus FOS (10 billion CFU/gram)
- Lactobacillus acidophilus DD-1 plus FOS (5 billion CFU/gram)
The company noted a recent clinical trial demonstrating the potential of a blend containing DDS-1, B. longum, B. lactis and B. bifidum to aid irritable bowel syndrome (IBS). The research was being prepared for clinical publication, Dr Dash said.
UAS Labs said its blends were room temperature stable with seven percent loss of potency in one year.
In its B2B literature, the company notes health benefits of its strains including:
- Human isolates that adapt well to the human body
- Acid and bile resistance that make it well-suited for intestinal survival
- Ability to promote digestive health
- Creates an unfavorable environment for pathogens
- Maintains natural immune defenses
- Contributes to good balance of intestinal flora